<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392816/" ref="ordinalpos=3600&amp;ncbi_uid=4111034&amp;link_uid=PMC3392816" image-link="/pmc/articles/PMC3392816/figure/F5/" class="imagepopup">Figure 5.  From: Extracellular nicotinamide phosphoribosyltransferase (NAMPT/visfatin) inhibits insulin-like growth factor-1 <span class="highlight" style="background-color:">signaling</span> and proteoglycan synthesis in human articular chondrocytes. </a></div><br /><div class="p4l_captionBody"><b>Model for inhibitory effect of extracellular nicotinamide phosphoribosyltransferase on insulin-like growth factor-1 function in chondrocytes</b>. In this hypothetical model, sustained activation of extracellular signal-regulated kinases (ERK) by extracellular nicotinamide phosphoribosyltransferase (eNAMPT) promotes increased phosphorylation of insulin receptor substrate-1 (IRS-1) (serine-312), which negatively regulates the downstream insulin-like growth factor-1 (IGF-1) signaling pathway and thereby matrix synthesis. IGF-1R, insulin-like growth factor-1 receptor.</div></div>